Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority